EG436059 Inhibitors
EG436059 inhibitors belong to a class of chemical compounds that exhibit the ability to specifically inhibit the activity of their target protein or pathway, often through binding and blocking the active site or a regulatory domain. These inhibitors are typically characterized by their small-molecule structure, allowing them to penetrate cellular membranes and modulate intracellular processes effectively. EG436059 inhibitors are known for their structural diversity, with various functional groups and ring systems that enable them to interact with a range of biological targets. These molecules often contain specific moieties that enhance their binding affinity and selectivity for their target, as well as chemical properties such as hydrophobicity or hydrogen-bonding capabilities that support their function.
The mechanism of action of EG436059 inhibitors is usually based on competitive binding, where they act as antagonists to the natural substrate or ligand of the target protein. By occupying the active site or altering the protein's conformation, these inhibitors disrupt normal biochemical activities, such as enzyme catalysis, signal transduction, or protein-protein interactions. The chemical design of these inhibitors frequently leverages structure-activity relationships (SARs) to fine-tune their efficacy and stability, leading to molecules with high specificity and minimized off-target effects. The binding affinities of EG436059 inhibitors can often be measured using biochemical assays, providing data on their potency and the kinetics of their interactions. This class of inhibitors is also characterized by its potential for chemical modification, where alterations to functional groups or side chains can greatly influence their selectivity, solubility, and overall biological activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X, a PKC inhibitor, directly inhibits protein kinase C (PKC) activity. Inhibition of PKC may indirectly impact AYAEV30TR, as PKC is involved in signaling pathways related to the regulation of gene expression, potentially modulating the activity of AYAEV30TR at the transcriptional level. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D, an RNA synthesis inhibitor, directly interferes with transcriptional processes. By inhibiting RNA synthesis, it may indirectly impact AYAEV30TR, disrupting the transcriptional machinery and potentially suppressing the expression of AYAEV30TR at the mRNA level. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, directly interferes with proteasomal degradation. Inhibition of proteasomal activity may indirectly impact AYAEV30TR, as the proteasome is involved in protein turnover and degradation, potentially leading to the accumulation of AYAEV30TR and altering its cellular functions. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, directly interferes with DNA methylation processes. Inhibition of DNA methylation may indirectly impact AYAEV30TR, as epigenetic modifications play a role in gene regulation, potentially altering the epigenetic landscape around the AYAEV30TR gene and influencing its transcriptional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, directly inhibits p38 mitogen-activated protein kinase (MAPK) activity. Inhibition of p38 MAPK may indirectly impact AYAEV30TR, as p38 MAPK is involved in signaling pathways related to stress response and gene expression regulation, potentially modulating the activity of AYAEV30TR under stress conditions. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone, an aldosterone receptor antagonist, directly inhibits aldosterone receptors. Inhibition of aldosterone receptors may indirectly impact AYAEV30TR, as aldosterone signaling is involved in cellular processes related to stress response and gene expression regulation, potentially modulating the activity of AYAEV30TR under conditions of hormonal influence. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin, a calcium ionophore, directly influences intracellular calcium levels. Modulation of calcium signaling may indirectly impact AYAEV30TR, as calcium is a key second messenger involved in various signaling pathways, potentially altering the activity of AYAEV30TR by influencing downstream signaling events. | ||||||
Tris Buffered Saline: 1 L of 1X | sc-362185 | 1 L | $21.00 | 3 | ||
Tubacin, a histone deacetylase 6 (HDAC6) inhibitor, directly interferes with HDAC6 activity. Inhibition of HDAC6 may indirectly impact AYAEV30TR, as HDAC6 is involved in the regulation of histone acetylation and protein stability, potentially modulating the epigenetic and proteostatic control of AYAEV30TR expression and function. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662, a PPARγ antagonist, directly inhibits peroxisome proliferator-activated receptor gamma (PPARγ). Inhibition of PPARγ may indirectly impact AYAEV30TR, as PPARγ is involved in the regulation of gene expression and cellular processes related to metabolism, potentially modulating the transcriptional activity of AYAEV30TR in response to metabolic cues. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, a CaMKII inhibitor, directly inhibits calcium/calmodulin-dependent protein kinase II (CaMKII) activity. Inhibition of CaMKII may indirectly impact AYAEV30TR, as CaMKII is involved in calcium-dependent signaling pathways related to gene expression and cellular processes, potentially modulating the activity of AYAEV30TR by influencing downstream signaling events. | ||||||